EUDA Health enters convertible loan agreement with Shenzhen Inno

EUDA Health (EUDA) Holdings entered into a convertible loan agreement with Shenzhen Inno Immune. Under the terms of the agreement, EUDA expects to invest up to RMB 6M in two tranches, consisting of an initial tranche of RMB 1M and a second tranche of RMB 5M, subject to the completion of due diligence, regulatory approvals, and execution of definitive agreements. Shenzhen Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA’s China strategy, anchoring EUDA’s regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion into additional cities and markets. The investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation. The convertible loan note is expected to carry an interest rate of 6% per annum, payable semi-annually, and may be redeemed with accrued interest if not converted, subject to the final terms.